BPC-157, KPV, & Larazotide Blend is cataloged as a multi-component research product. The site's structured catalog data lists three components: BPC-157, KPV, and larazotide (cataloged under synonyms including Larazotide Acetate and AT-1001). The combination has not been established as a single pharmacologic entity; component identity, purity, and interactions should be confirmed against the supplier's certificate of analysis before laboratory use.
BPC-157 has been investigated mainly in preclinical systems, including work connecting it with VEGFR2-Akt-eNOS signaling; its molecular target is not established. KPV is the C-terminal tripeptide of alpha-MSH and has been studied in cell and animal models involving NF-kappaB and other inflammatory-signaling pathways; its direct target and behavior in this blend remain uncertain. Larazotide is an octapeptide investigated as a tight-junction regulator; proposed mechanisms include zonulin-pathway antagonism and modulation of myosin light-chain kinase. The exact mechanism remains under study and must not be generalized to this blend without verification. No established mechanism of action exists for the combined formulation; the component notes must not be interpreted as evidence of additive or synergistic activity.